Ultimovacs (ULTI) småprat 1

[TekBot]

Ultimovacs ASA: Fourth quarter 2021 result presentation

Oslo, 17 February 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical
stage leader in immune stimulatory vaccines for cancer, announces its fourth
quarter 2021 results today.
…

Vis børsmeldingen

The presentation by the company’s management team can be followed as a live
webcast (https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20220217_12)
at 09:00 CET and will be made available on the website. It will be possible to
post questions during the presentation through the webcast.

Highlights for the fourth quarter of 2021:

• On December 2, 2021, Ultimovacs announced that UV1 received Orphan Drug
  designation from the U.S. FDA in the treatment of malignant melanoma.
• On October 26, 2021, Ultimovacs announced a new Phase II clinical trial
  (LUNGVAC) investigating UV1 in combination with pembrolizumab in non-small
  cell lung cancer (NSCLC). (also presented in the Q3 report)
• On October 20, 2021, Ultimovacs announced that UV1 received Fast Track
  designation from the U.S. FDA in the treatment of unresectable or metastatic
  melanoma. (also presented in the Q3 report)
• On October 13, 2021, Ultimovacs announced that the overall survival rate
  after two years of follow-up in the Phase I clinical trial of UV1 combined
  with pembrolizumab was 80% in this first cohort of 20 patients. (also
  presented in the Q3 report)

Clinical trial enrollment update

• INITIUM trial: 120 patients have been enrolled to date, up from 91 as of the
  previous quarterly report.

• NIPU trial: 66 patients have been enrolled to date, up from 45 as of the
  previous quarterly report.

• FOCUS trial: 10 patients have been enrolled to date, up from 5 as of the
  previous quarterly report.

• DOVACC trial: The first patient was enrolled on 15 December 2021, and 2
  patients have been enrolled to date.

• TENDU trial: 6 patients have been enrolled to date in this dose escalation
  study compared to 4 patients in the previous quarterly report, completing
  treatment of the second cohort. No safety concerns emerged in the first two
  dose level cohorts, allowing the enrollment of patients in the third, final
  dose cohort.

• COVID-19: Although Ultimovacs remain optimistic regarding progress in the
  Company’s broad clinical program, the effect of the pandemic on the biotech
  industry and the conduct of clinical trials is still uncertain.
  Ultimovacs will continue to provide enrollment updates in each quarterly
  report.

• Despite earlier and current pandemic-related challenges, the levels of
  patient enrollment have been increasing recently in both the INITIUM and
  NIPU studies. Ultimovacs’ updated guidance is that both studies are
  estimated to have readouts during the first half of 2023, rather than during
  the second half of 2022 as indicated in the early guidance given in 2019
  before either study started.

• The DOVACC and FOCUS trials are still in their early stages of
  hospitals/clinical site activation, and the start-up phase of both has taken
  somewhat longer than originally planned. Ultimovacs has guided that the
  readouts of topline results are expected to take place in 2023 and have done
  so since the trials began. In the LUNGVAC trial, Ultimovacs expects the
  first patient to be enrolled during the first half of 2022 with topline
  results expected by the end of 2024. Once each of these trials has
  progressed sufficiently to provide a reliable trajectory beyond initiation,
  Ultimovacs will review guidance and expect to give an update with the Q4
  2022 report.

Financial

• Total operating expenses amounted to MNOK 50.9 in Q4-21, and MNOK 163.8 in
  FY21.
• Net negative cash flow from operations was MNOK 33.9 in Q4-21, and MNOK
  125.8 in FY21. Total cash and cash equivalents increased by MNOK 227.9
  during Q4-21 and amounted to MNOK 574.2 as per 31 December 2021.
• A private placement was successfully completed on October 26, 2021, raising
  gross proceeds of MNOK 270 (net MNOK 259.0). (also presented in the Q3-
  report)

The report and presentation are also available on the Company website:

www.ultimovacs.com/investors/reports-and-presentations

For further information, please visit www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507

Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632

Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com
Phone: +44 7483 284 853

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Joachim Midttun, Finance
Manager at Ultimovacs ASA, on 17 February, 2021 at 08:00 CET.

Kilde

[polygon]

Veldig bra rekruttering! Utsatt guiding av INITIUM og NIPU til 1H23, men det foreventet jo alle. Mitt regneark for INITIUM sier at denne guidingen egentlig er 1Q23, faktisk med ganske god margin også.

En ting er at rekrutteringstakten er fin for utålmodige aksjonærer. Minst like viktig er at dette jo er resultatet av engasjerte klinikere verden over som har troen på UV1 og faktisk anbefaler sine pasienter å blir med i dette kliniske forsøket.

[h3nk1]

29 nye i INITIUM?? 21 NIPU? Ser jeg feil? Fantastisk. De må ha eget tilvalg for Møllers Tran på kaffemaskinen i Ullernchausseen.

Edit:

Om jeg regner riktig videre, så ligger de nå an til avlesning Q1 23. Å bli et par-tre måneder (!) forsinket på opprinnelig guiding fra 2019 FØR pandemien er rett og slett en stor bragd teamet fortjener stor honnør for.

[theroger]

Ultimovacs doblet driftstapet

Biotek-sjef kjøper liten aksjepost

[SoriaMoria]

Noen som kan poste lenke til webcasten?

[polygon]

Hvis de fortsetter med det, så er de konkurs om tre kvartaler da. Selg!

EDIT: Oj! Dette var altså en ironisk kommentar til hvor komplett unyttig og usaklig norsk finansepresse behandler det som er en fremtidig viktig bransje i norsk økonomi.

[theroger]

https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20220217_12

[Syvcys]

Polygon, alvorlig ment eller?
550/50 er vel 11 ikke 3!

[Fornybar]

Ikke hvis de fortsetter å doble tapet

[Mulligan]

På s. 20 i presentasjonen sies det at de har tilstrekkelig finansiering til første del av 2024.

[Fornybar]

Vi tøyser mye her. Ultimovacs har full kontroll og leverer fremragende.

De har penger til store verdidrivende triggere.
De har økt rekrutteringen igjen og flytter bare readout med noen kvartaler etter to års pandemi.

[Syvcys]

Fornybar, doble tapet hvert kvartal, det er sannsynlig ja50;100;200, nei bare tull.

[Fartin]

Ja om markedet er skuffet over dette da burde alle solgt i går … snakk om å levere over forhåpningene…

[polygon]

Veldig viktig: “the good data so far have supported the interest from patients”

[Fartin]

De ble vel være ferdig rekruttert innen to måneder i initium om de opprettholder dette tempoet?

[polygon]

Blir nok ikke før i mai. Men det betyr fortsatt at man vet om UV1 har effekt (som er det de guider på) allerede i 1Q23.

…og dette var over forventning. Men nå må tydeligvis de ytterst få, som ikke følger med, få solgt sine aksjer ferdig.

[Bingo123]

Hva kan være årsaken til nedgangen i dag? Er det noe i rapporten som skuffer markedet ?
Har sett dette før. Topp stemning her, mens markedet mener noe helt annet. Det er nesten ikke kjøpere og kursen er 93

[kula]

@polygon

Men nå må tydeligvis de ytterst få, som ikke følger med, få solgt sine aksjer ferdig.

Mulig de bare har lest overskriften i FA

[Birgitte]

Det eneste nye i dag var rekrutteringstallene - og de var meget gode.

Nyheter kommer når de kommer - man kan ikke bestille slikt til en Q presentasjon.

Mye uvitenhet og tøvete kommentarer i dag.

La de selge de som vil og som ikke har perspektiv ut over egne skotupper.

[MariusJ]

Har kjøpt selv idag. Kan ikke skjønne annet enn at det er utålmodighet som er drivkraft til salg idag. Legger de nye aksjene sammen med de andre på kistebunn og tar de frem om et års tid.